General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-08-21 | 2023-06 | 0 | N/A | N/A | N/A |
2023-05-15 | 2023-03 | 0 | N/A | N/A | N/A |
2023-03-16 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-14 | 2022-09 | 0 | N/A | N/A | N/A |
2022-08-10 | 2022-06 | -2.8 | N/A | N/A | N/A |
2022-05-16 | 2022-03 | -2.1 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2020-05-13 | Maxim Group | Upgrade | Hold | Buy |
2019-11-26 | Raymond James | Downgrade | Outperform | Market Perform |
2019-11-25 | Maxim Group | Downgrade | Buy | Hold |
2019-07-23 | B. Riley FBR | Upgrade | Sell | Neutral |
2019-07-16 | B. Riley | Downgrade | Neutral | Sell |
2018-11-12 | B. Riley FBR | Downgrade | Buy | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-03-17 | BENEDICTO DAVID C. | Chief Financial Officer | 39.88K | Sale |
2022-05-24 | CARLO DENNIS J | Former | 692.46K | Conversion of Exercise of derivative security |
2020-11-17 | DANIELS KAREN K | Officer | 149.24K | Sale |
2023-05-24 | DESAI MEERA J. | Director | 3.14K | Stock Award(Grant) |
2021-02-18 | HOPKINS ROBERT O | Chief Financial Officer | 277.07K | Conversion of Exercise of derivative security |
2022-03-17 | MARGUGLIO DAVID J | Officer and Director | 239.79K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Armistice Capital, LLC | 207.15K | 484.72K | 0.12% |
2023-03-30 | Vanguard Group, Inc. (The) | 92.63K | 216.75K | 0.05% |
2023-03-30 | Blackrock Inc. | 39.53K | 92.50K | 0.02% |
2023-03-30 | Geode Capital Management, LLC | 18.95K | 44.35K | 0.01% |
2023-03-30 | State Street Corporation | 6.79K | 15.89K | 0.00% |
2023-03-30 | Citadel Advisors Llc | 4.67K | 10.94K | 0.00% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | Vanguard Total Stock Market Index Fund | 4.10M | 9.58M | 2.73% |
2022-12-30 | Vanguard Extended Market Index Fund | 2.11M | 4.93M | 1.40% |
2023-02-27 | Fidelity Extended Market Index Fund | 783.33K | 1.83M | 0.52% |
2023-02-27 | Fidelity Total Market Index Fund | 200.21K | 468.48K | 0.13% |
2023-02-27 | Fidelity Series Total Market Index Fund | 167.25K | 391.37K | 0.11% |
2022-12-30 | Vanguard Institutional Index-Inst Total Stock Market Ind | 114.37K | 267.62K | 0.08% |
Split | Date |
---|---|
1 : 70 | 2023-05-22 |
0.05882 : 1 | 2013-12-13 |
0.10072 : 1 | 2009-04-22 |
FU SHORTS.... WANNA RECONSIDER?
Here comes the big gain !
MAKE IT HAPPEN!!!!!
BRIEF-Adamis Pharmaceuticals Says Q3 Revenue Increased About 54% To $5.9 Mln
BY Reuters
6:02 PM ET 11/12/2019
QTRLY REVENUES INCREASED APPROXIMATELY 54%, FROM $3.8 MILLION TO $5.9 MILLION
CASH AND EQUIVALENTS AT END OF Q3 WAS APPROXIMATELY $12.1 MILLION. Source text for Eikon: Further company coverage:
So Shorts, the Dollar Store will have Christmas presents still for the family. Not a total loss.
Alexander Rod
We understand, that you have no intention on buying any shares of ADMP... With that said, do you just enjoy spreading propaganda throughout Investment boards...? Your motive is clear and we feel that nows the time to take your ball and leave so the big kids can play....
And for the major investment firms and institutions that aren’t interested in ADMP, well maybe you can spend your time calling them and informing them how crazy they are for investing 100’s and thousands of shares in ADMP....
@ ALEXANDER ROD
I think we all know, but what’s your motive here...? Are you truly and sincerely doing us all a big favor...? I’m curious...
DON’T MISS the obvious here.....$$$$
EARNINGS WILL CARRY....$$$$$
Q1 2019 $4,905,772 (2018 $3,179,235)
Q2 2019 $5,764,899 (2018 $3,920,566)
Q3 2019 $??.?????? This Thursday.....
Positive news from FDA, along with another strong quarter on earnings.... C’MON....!